|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.92 EUR | +1.01% |
|
+3.29% | +9.14% |
| 06-12 | European Stocks Close Higher; German Inflation Cools, UK GDP Contracts | MT |
| 06-12 | GSK's Clonal Myeloid Disorder Treatment Gets Orphan Drug Designation From US, European Regulators | MT |
| Market Cap | 79.2B 106B 91.82B 84.61B 148B 10,105B 151B 999B 390B 4,918B 399B 390B 17,030B | P/E Ratio 2026 * |
12.7x | P/E Ratio 2027 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 93.45B 125B 108B 99.84B 175B 11,923B 178B 1,179B 460B 5,803B 471B 461B 20,094B | EV / Sales 2026 * |
2.77x | EV / Sales 2027 * | 2.55x |
| Free-Float |
92.3% | Yield 2026 * |
3.53% | Yield 2027 * | 3.69% |
Last Transcript: GSK plc
| 1 day | +1.01% | ||
| 1 week | +3.29% | ||
| Current month | +6.06% | ||
| 1 month | +6.06% | ||
| 3 months | -1.55% | ||
| 6 months | +10.62% | ||
| Current year | +9.14% |
| 1 week | 21.35 |  | 22.99 |
| 1 month | 20.91 | | 22.99 |
| Current year | 20.27 | | 26.02 |
| 1 year | 15.35 | | 26.02 |
| 3 years | 14.68 | | 26.02 |
| 5 years | 14.62 | | 27.13 |
| 10 years | 14.62 | | 27.52 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.01% | +3.29% | - | - | 106B | |
| -2.41% | +0.14% | +38.28% | +154.20% | 1,010B | |
| +1.07% | +3.48% | +53.32% | +49.85% | 580B | |
| +1.32% | +0.22% | +19.18% | +64.65% | 402B | |
| +0.77% | 0.00% | +21.28% | +16.70% | 330B | |
| +0.44% | +3.48% | +25.65% | +35.66% | 281B | |
| -0.85% | -2.86% | +22.54% | +14.67% | 280B | |
| +1.66% | +1.20% | -44.35% | -47.35% | 197B | |
| +0.32% | +1.61% | +20.32% | +60.01% | 192B | |
| -0.22% | -2.76% | +14.19% | +60.09% | 156B | |
| Average | +0.31% | +0.84% | +18.93% | +45.39% | 380.99B | |
| Weighted average by Cap. | -0.19% | +1.04% | +27.77% | +70.54% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.78B 45.35B 39.17B 36.09B 63.31B 4,310B 64.29B 426B 166B 2,098B 170B 167B 7,264B | 35.48B 47.62B 41.13B 37.9B 66.49B 4,526B 67.52B 448B 174B 2,203B 179B 175B 7,628B |
| Net income | 6.27B 8.41B 7.26B 6.69B 11.74B 799B 11.93B 79.05B 30.82B 389B 31.57B 30.89B 1,347B | 6.67B 8.95B 7.73B 7.12B 12.5B 851B 12.69B 84.13B 32.8B 414B 33.6B 32.88B 1,434B |
| Net Debt | 14.25B 19.13B 16.52B 15.23B 26.71B 1,818B 27.12B 180B 70.1B 885B 71.8B 70.27B 3,064B | 11.19B 15.02B 12.97B 11.95B 20.97B 1,428B 21.29B 141B 55.03B 695B 56.37B 55.17B 2,406B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/06/26 | 22.92 € | +1.01% | 1,290 |
| 11/06/26 | 22.69 € | +1.89% | 500 |
| 10/06/26 | 22.27 € | +1.04% | 568 |
| 09/06/26 | 22.04 € | +0.59% | 222 |
| 08/06/26 | 21.91 € | -1.26% | 210 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GS71 Stock
Select your edition
All financial news and data tailored to specific country editions
